Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models
Open Access
- 13 April 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Signal Transduction and Targeted Therapy
- Vol. 3 (1), 1-9
- https://doi.org/10.1038/s41392-018-0010-0
Abstract
In addition to their canonical roles in regulating cell cycle transition and transcription, cyclin-dependent kinases (CDKs) have been shown to coordinate DNA damage response pathways, suggesting a rational pairing of CDK inhibitors with genotoxic chemotherapeutic agents in the treatment of human malignancies. Here, we report that roniciclib (BAY1000394), a potent pan-CDK inhibitor, displays promising anti-neoplastic activity as a single agent and potentiates cisplatin lethality in preclinical nasopharyngeal carcinoma (NPC) models. Proliferation of the NPC cell lines HONE-1, CNE-2, C666-1, and HK-1 was effectively curbed by roniciclib treatment, with IC50 values between 11 and 38 nmol/L. These anticancer effects were mediated by pleiotropic mechanisms consistent with successful blockade of cell cycle CDKs 1, 2, 3, and 4 and transcriptional CDKs 7 and 9, ultimately resulting in arrest at G1/S and G2/M, downregulation of the transcriptional apparatus, and repression of anti-apoptotic proteins. Considerably enhanced tumor cell apoptosis was achieved following combined treatment with 10 nmol/L roniciclib and 2.0 μmol/L cisplatin; this combination therapy achieved a response over 250% greater than either drug alone. Although roniciclib chemosensitized NPC cells to cisplatin, it did not sensitize untransformed (NP69) cells. The administration of 0.5 mg/kg roniciclib to BALB/c xenograft mice was well tolerated and effectively restrained tumor growth comparable to treatment with 6 mg/kg cisplatin, whereas combining these two agents produced far greater tumor suppression than either of the monotherapies. In summary, these data demonstrate that roniciclib has strong anti-NPC activity and synergizes with cisplatin chemotherapy at clinically relevant doses, thus justifying further evaluation of this combinatorial approach in clinical settings.Keywords
This publication has 38 references indexed in Scilit:
- Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cellsProceedings of the National Academy of Sciences of the United States of America, 2012
- BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral ApplicationMolecular Cancer Therapeutics, 2012
- Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approachesSeminars in Cancer Biology, 2012
- Nasopharyngeal carcinomaAnnals of Oncology, 2010
- Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA DamageMolecular Cell, 2009
- Cell cycle, CDKs and cancer: a changing paradigmNature Reviews Cancer, 2009
- Combined Depletion of Cell Cycle and Transcriptional Cyclin-Dependent Kinase Activities Induces Apoptosis in Cancer CellsCancer Research, 2006
- Nucleophosmin and cancerNature Reviews Cancer, 2006
- Cdc2–cyclin E complexes regulate the G1/S phase transitionNature, 2005
- Preclinical and Clinical Development of the Cyclin-Dependent Kinase Inhibitor FlavopiridolClinical Cancer Research, 2004